CNS Pharmaceuticals (NASDAQ: CNSP) is a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system (“CNS”). The company today announced that its ongoing potentially pivotal study evaluating Berubicin for the treatment of recurrent glioblastoma multiforme (“GBM”), an aggressive and incurable form of brain … Continue reading “NetworkNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Achieves 50%+ Enrollment in Potentially Pivotal Berubicin Study”
CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, today announced its financial results for the quarter ended March 31, 2023. In addition, the company provided a clinical update of its anti-cancer drug candidate currently in development for … Continue reading “NetworkNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Announces Q1 2023 Results, Corporate Update”
CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, today announced its appointment of Bettina M. Cockroft, M.D., M.B.A., to its board of directors. Dr. Cockroft, a well-established industry executive with over 30 years of experience in the … Continue reading “NetworkNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Announces Board Appointment of Pharma and Biotech Industry Veteran Dr. Bettina M. Cockroft”
CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, is investigating potential naked short selling of its stock. As part of that process, the company has retained Shareholder Intelligence Services LLC (ShareIntel), a well-known analytics firm. ShareIntel will … Continue reading “NetworkNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Retains Analytics Firm, Investigates Possible Naked Short Selling”
CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, will be presenting at an upcoming Virtual Investor Spotlight Event. The event is titled Virtual Investor Spotlight Event – Rapidly Advancing GBM Pivotal Study. According to the announcement, the live, moderated … Continue reading “NetworkNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) to Participate, Present at Upcoming Virtual Investor Spotlight Event”
CNS Pharmaceuticals (NASDAQ: CNSP) recently reported the enrollment of the first patient in Switzerland as a participant in its ongoing potentially pivotal global trial evaluating Berubicin for the treatment of glioblastoma multiforme (“GBM”). “CNS Pharmaceutical’s adaptive, multicenter, open-label, randomized controlled study targets adult patients with recurrent GBM after failure of standard first-line therapy. In addition, … Continue reading “NetworkNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Advancing Potentially Pivotal Berubicin Trial”
For decades, medical science has sought an effective means of stopping the most common primary brain cancer in adults in its tracks and keeping it from recurring. In spite of multimodal treatment that includes surgical removal, radiotherapy and chemotherapy, glioblastoma tumors remain the deadliest form of brain cancer and are essentially incurable, leaving patients with … Continue reading “CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) Global Trial Targets Unmet Medical Need in Arresting GBM Brain Cancer”
CNS Pharmaceuticals (NASDAQ: CNSP), a clinical-stage biotechnology company specializing in the development of novel treatments, recently reported the enrolment of the first patient in Switzerland as a participant in its ongoing potentially pivotal global trial evaluating Berubicin for the treatment of recurrent glioblastoma multiforme (“GBM”) (https://nnw.fm/2oa0k). An aggressive, fast-growing primary brain tumor, GBM accounts for … Continue reading “CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) Enrolls First Patient in Switzerland in Its Potentially Pivotal Global GBM Trial, Reports No Exposure to SVB Issues”
CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, today announced that more than 100 patients have been enrolled in the company’s potentially pivotal study with its lead product candidate, Berubicin. “We have long promised a study with … Continue reading “NetworkNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Enrolls Over 100 Patients in Potentially Pivotal Berubicin Study”
CNS Pharmaceuticals (NASDAQ: CNSP) today announced its receipt of approval from the Italian Medicines Agency (“AIFA”) Competent Authority and the A.O.U. Policlinico di Bari Ethics Committee for its ongoing potentially pivotal global trial evaluating Berubicin for the treatment of recurrent glioblastoma multiforme (“GBM”), an aggressive and incurable form of brain cancer. According to the update, … Continue reading “NetworkNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Adds Italy to Growing Portfolio of Countries for Berubicin Study”
